论文部分内容阅读
目的观察新型免疫抑制来氟米特(商品名:爱若华)治疗表现为肾病综合征的过敏性紫瘢性肾炎的疗效和安全性。方法经肾活检证实的过敏性紫瘢性肾炎,以肾病综合征为表现的住院患者36例,同期按1∶1随机分为来氟米特组和常规治疗对照组,总疗程6个月,观察治疗前后24h尿蛋白定量,尿红细胞计数等指标变化,按照疗效评定标准对比分析来氟米特组与常规治疗对照组的疗效和安全性。结果用药后3个月和6个月两组24h尿蛋白定量较治疗前均显著下降,血浆白蛋白水平显著升高,尿沉渣红细胞计数减少(P<0.05)。3个月后,来氟米特治疗组较环磷酰胺对照疗效差异无统计学意义(P>0.05),但6个月后疗效治疗组较对照组有统计学意义(P<0.05)。结论来氟米特是治疗表现为肾病综合征的紫瘢性肾炎的一种安全、有效的药物,优于环磷酰胺组。
Objective To observe the efficacy and safety of the novel immunosuppressive leflunomide (trade name: Ai Ruohua) in the treatment of allergic hyperthyroidism with nephrotic syndrome. Methods 36 cases of allergic purple myelitis confirmed by renal biopsy and nephrotic syndrome were randomly divided into leflunomide group and routine treatment control group according to 1: 1. The total course of treatment was 6 months, Urinary protein excretion and urinary erythrocyte count were observed 24 hours before and after treatment. The efficacy and safety of leflunomide group and conventional treatment control group were compared and analyzed according to the standard of efficacy evaluation. Results The urinary protein excretion of 24hours and24hours after treatment were significantly lower than before treatment, the level of plasma albumin was significantly increased, and the urinary sediment erythrocyte count was decreased (P <0.05). After 3 months, there was no significant difference in efficacy of leflunomide compared with cyclophosphamide (P> 0.05), but after 6 months of treatment, the effect of treatment group was statistically significant (P <0.05). Conclusions Leflunomide is a safe and effective drug for the treatment of scleritis with nephrotic syndrome, which is superior to the cyclophosphamide group.